Long-Term, Real-World, Kidney Function Changes with SGLT2i versus DPP4i Type 2 Diabetes without Cardiovascular or Kidney Disease.
Cheli Melzer CohenMeir SchechterAliza RozenbergIlan YanuvDvora R Sehtman-ShacharAlisa FishkinDoron RosenzweigGabriel ChodickAvraham KarasikLawrence A LeiterPublished in: Clinical journal of the American Society of Nephrology : CJASN (2023)
Long-term use of SGLT2i versus DPP4i in a real-world setting was associated with mitigation of eGFR loss in patients with type 2 diabetes, even in those lacking evidence of cardiovascular or kidney disease at baseline.